Business Wire

CA-CONVIVA

9.9.2022 12:21:36 CEST | Business Wire | Press release

Share
Worldwide Streaming Market Achieves Double-digit Growth in Q2 2022; Smart TVs and Roku Dominate Global Viewing According to Conviva

Conviva, the global streaming analytics platform, released today the results of its quarterly State of Streaming Report, which shows continued growth in the global streaming market, including gains of (14%) in the second quarter of 2022 as compared to Q2 2021. Asia and Latin America saw the most growth — 90% and 70%, respectively — while North America, the most mature streaming market in the world, also grew 5% year over year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220909005099/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Conviva's State of Streaming Report Q2 2022 (Graphic: Business Wire)

As the global streaming industry matures, streaming success is getting more complicated. Device fragmentation is growing, and viewers’ quality expectations continue rising in concert with an ad-supported streaming world. Streaming publishers are challenged to deliver a consistent and positive experience. Whether in Africa using an Android phone or in Texas on a Smart TV – viewers expect a quality picture, instant access to content and zero glitches.

“The race is on to see which publishers will meet these expectations, including providing the best experience when it’s most important,” said Keith Zubchevich, President and CEO, Conviva. “Those who do will quickly eclipse the competition. Most importantly, those who make it a priority to obtain real-time actionable insights about their customers’ (real-world experiences) will undoubtedly separate the leaders from the pack,” added Zubchevich.

Key Findings

Bitrates are Rising

Conviva found bitrate rose globally in Q2 2022 across all screen types and devices, but often at the expense of other quality metrics. For example, Smart TVs saw the largest increase in bitrate of all screen types, up 15.1% year over year. However, to provide this more high-definition experience, Smart TVs saw noticeable increases in video start failures, video start time and buffering. Conversely, PlayStation and Roku were the only big screen devices to both decrease video start times (down 10.7% and 12% respectively) and increase bitrate (up 4.6% and 12.9% respectively).

Big Screens – and Roku – Remain on Top

Roku continued to hold the top spot among big screen devices (big screens include connected TVs, Smart TVs and gaming consoles), holding nearly steady at 30.5% of viewing time, down less than one percent as compared to Q2 2021 with Amazon Fire TV coming in second with 16% of big screen viewing time. Samsung TV (13.7%), Android TV (7.8%) and LG TV (7.3%) rounded out the top five devices for big screen viewing time. Chromecast, Xbox and PlayStation all saw a decrease in share as compared to the previous year.

Android vs iPhone Streaming Showdown

To date, the iPhone has been the primary device for mobile streaming, especially in North America. In Q2 2022 the gap closed, with iPhone and Android phones capturing nearly identical global market share, 35.8% vs 33.2% respectively. In addition, Android phones outpaced the iPhone by 10% in YoY growth in streaming viewing hours. In Apple’s favor is its quality — as the iPhone currently beats Android phones in every quality category. As streaming publishers expand into newer, less mature streaming markets outside of North America, optimizing the streaming experience for the android mobile device market will be of increasing importance.

Methodology

Conviva’s State of Streaming series is the largest cross-platform comparison of streaming data measuring ongoing, real-time, sessionized streaming data at Internet-scale.

Data analyzed for the Q2 2022 State of Streaming report was primarily collected from Conviva’s unique proprietary sensor technology. Currently embedded in 3.3 billion streaming video applications, it measures more than 500 million unique viewers watching 180 billion streams per year and nearly 2 trillion real-time transactions per day across more than 180 countries. The Internet-scale census-measurement is deployed from a full-stack censor that is not sampled, but validated, cleaned, enriched, standardized and sessionized. Continuous, real-time monitoring sessionizes streaming events, state timelines and meta data into viewer-led sessions. This more accurately reflects viewers’ real-world experiences.

The social media data, collected from the Streaming Publishers leaderboard list within Conviva Social Insights, consists of data from 100 accounts, over 7,500 million posts, and over 30 million engagements across Facebook, Instagram, Twitter, TikTok and YouTube between Q2 2021 and Q2 2022.

Year-over-year comparisons were normalized at the customer level for accurate representations of industry growth.

Get a copy of Conviva’s Q2 State of Streaming Report

About Conviva

Conviva is the only global streaming analytics platform for big data that collects, standardizes, and puts trillions of streaming data points in context, in real time. With Conviva, streaming businesses can understand real-world human experiences within seconds of observation and take action to grow their business ahead of the competition.

The Conviva platform provides comprehensive, continuous, census-level measurement through real-time, server side sessionization at scale. It includes first-of-its kind-innovations like time-state analytics and AI automated data modeling. Using a single full stack sensor at the source, coupled with a single big data pipeline, Conviva’s 60+ patent platform enables marketers, advertisers, tech ops, engineering and customer care teams to acquire, engage, monetize and retain their audiences. Conviva is dedicated to supporting brands like DAZN, Disney+, Hulu, Paramount+, Peacock, Sky, Sling TV, TED and WarnerMedia as they unlock incredible opportunity with streaming analytics. To learn more, visit www.conviva.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220909005099/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

ProcureTEX Returns for Its Second Year, Bringing AI and Best-of-Breed Procurement Technology to Amsterdam14.10.2026 18:26:00 CEST | Press release

Founding partners Beroe, Keelvar and Zip bring back the community-driven event with a practitioner-shaped agenda spanning real-world AI use and the future of procurement ProcureTEX, the community-driven event for best-of-breed procurement technology, returns for its second year on November 3, 2026, at Circa in Amsterdam. Following its London debut in 2025, the event sharpens its focus on how AI is reshaping procurement. It will bring together over 250 procurement leaders and digital transformation teams from large enterprises, with vetted best-of-breed technology providers, to see AI agents and interoperable tools working together on real enterprise challenges. Co-founded by Beroe, Keelvar and Zip, the event is built on the belief that the future of procurement isn’t a monolithic all-in-one suite, but an ecosystem of best-of-breed tools working together. It is designed for procurement and enterprise leaders seeking scalable, modern solutions, whether they’re driving transformation, fru

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye